{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:48:26Z","timestamp":1786934906808,"version":"build-2736575974"},"reference-count":222,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":1054,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s13311-020-00875-w","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T13:07:50Z","timestamp":1591621670000},"page":"1511-1524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Management of psychiatric disorders in Parkinson's disease"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0633-7168","authenticated-orcid":false,"given":"Daniel","family":"Weintraub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-020-00875-w_bib1","doi-asserted-by":"crossref","unstructured":"Martinez-Martin P, Wan YM, Ray Chaudhuri K, Schrag AE, Weintraub D. Impulse control and related behaviors in Parkinson's disease with dementia. Eur J Neurol. 2020.","DOI":"10.1111\/ene.14169"},{"key":"10.1007\/s13311-020-00875-w_bib2","unstructured":"Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely and Jones; 1817 1817."},{"issue":"9","key":"10.1007\/s13311-020-00875-w_bib3","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/mds.27115","article-title":"Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy","volume":"32","author":"Obeso","year":"2017","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-020-00875-w_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","article-title":"Non-motor symptoms of Parkinson's disease: diagnosis and management","volume":"5","author":"Chaudhuri","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1007\/s13311-020-00875-w_bib5","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/mds.23664","article-title":"Parkinson's disease: the quintessential neuropsychiatric disorder","volume":"26","author":"Weintraub","year":"2011","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41531-018-0058-0","article-title":"Prevalence of Parkinson's disease across North America","volume":"4","author":"Marras","year":"2018","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1007\/s13311-020-00875-w_bib7","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib8","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1136\/bmj.320.7245.1287","article-title":"Depression in Parkinson's disease","volume":"320","author":"Allain","year":"2000","journal-title":"British Medical Journal."},{"key":"10.1007\/s13311-020-00875-w_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/archneur.1996.00550020087019","article-title":"The occurrence of depression in Parkinson's disease. A community-based study","volume":"53","author":"Tandberg","year":"1996","journal-title":"Archives of Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/mds.870130109","article-title":"Depression in classic versus akinetic-rigid Parkinson's disease","volume":"13","author":"Starkstein","year":"1998","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mds.21803","article-title":"A systematic review of prevalence studies of depression in Parkinson's disease","volume":"23","author":"Reijnders","year":"2008","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.parkreldis.2008.01.016","article-title":"Frequency and treatment of depressive symptoms in a Parkinson's disease registry","volume":"14","author":"Althaus","year":"2008","journal-title":"Parkinsonism and Related Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1353-8020(01)00015-3","article-title":"Non-recognition of depression and other non-motor symptoms in Parkinson's disease","volume":"8","author":"Shulman","year":"2002","journal-title":"Parkinsonism and Related Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/0891988703256053","article-title":"Recognition and treatment of depression in Parkinson's disease","volume":"16","author":"Weintraub","year":"2003","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"key":"10.1007\/s13311-020-00875-w_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00005053-199001000-00005","article-title":"Depression in Parkinson's disease","volume":"178","author":"Starkstein","year":"1990","journal-title":"Journal of Nervous and Mental Disease."},{"key":"10.1007\/s13311-020-00875-w_bib16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1034\/j.1600-0447.2002.02045.x","article-title":"Markers for depression in Parkinson's disease","volume":"106","author":"Leentjens","year":"2002","journal-title":"Acta Psychiatrica Scandinavica."},{"key":"10.1007\/s13311-020-00875-w_bib17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/jnp.8.1.20","article-title":"Depression and disability in Parkinson's disease","volume":"8","author":"Cole","year":"1996","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences."},{"key":"10.1007\/s13311-020-00875-w_bib18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.1042","article-title":"Exacerbated physical fatigue and mental fatigue in Parkinson's disease","volume":"16","author":"Lou","year":"2001","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archneur.56.5.595","article-title":"Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study","volume":"56","author":"Aarsland","year":"1999","journal-title":"Archives of Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000129843.15756.A3","article-title":"Psychiatric comorbidities in patients with Parkinson disease and psychosis","volume":"63","author":"Marsh","year":"2004","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib21","first-page":"23","article-title":"Insomnia and depressive symptoms in patients with Parkinson's disease. Relationship to health-related quality of life","volume":"32","author":"Caap-Ahlgren","year":"2001","journal-title":"An interview of patients living at home. Archives of Gerontology and Geriatrics."},{"key":"10.1007\/s13311-020-00875-w_bib22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/0891988704267456","article-title":"Depression in Parkinson's disease: conceptual issues and clinical challenges","volume":"17","author":"Leentjens","year":"2004","journal-title":"Journal of Geriatric Psychiatry and Neurology."},{"issue":"12","key":"10.1007\/s13311-020-00875-w_bib23","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1212\/WNL.0b013e3182a4a503","article-title":"Modeling depression in Parkinson disease: disease-specific and nonspecific risk factors","volume":"81","author":"Leentjens","year":"2013","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1176\/jnp.15.1.74","article-title":"The contribution of somatic symptoms to the diagnosis of depression in Parkinson's disease: a discriminant analytic approach","volume":"15","author":"Leentjens","year":"2003","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences."},{"key":"10.1007\/s13311-020-00875-w_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1600-0447.1994.tb01558.x","article-title":"Suicide in patients with Parkinson's disease: an epidemiological study","volume":"90","author":"Stenager","year":"1994","journal-title":"Acta Psychiatrica Scandinavica."},{"key":"10.1007\/s13311-020-00875-w_bib26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/089198870101400304","article-title":"Are patients with Parkinson's disease suicidal?","volume":"14","author":"Myslobodsky","year":"2001","journal-title":"Journal of Geriatric Psychiatry and Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/WNL.43.3_Part_1.505","article-title":"Dopamine-related personality traits in Parkinson's disease","volume":"43","author":"Menza","year":"1993","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.parkreldis.2018.01.013","article-title":"Personality and Parkinson's disease: A meta-analysis","volume":"49","author":"Santangelo","year":"2018","journal-title":"Parkinsonism Relat Disord."},{"key":"10.1007\/s13311-020-00875-w_bib29","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/mds.22130","article-title":"Suicidal and death ideation in Parkinson's disease","volume":"10","author":"Nazem","year":"2008","journal-title":"Movement Disorders"},{"key":"10.1007\/s13311-020-00875-w_bib30","doi-asserted-by":"crossref","unstructured":"Shepard MD, Perepezko K, Broen MPG, Hinkle JT, Butala A, Mills KA, et al. Suicide in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2019.","DOI":"10.1136\/jnnp-2018-319815"},{"issue":"5","key":"10.1007\/s13311-020-00875-w_bib31","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1001\/jama.2019.21834","article-title":"Association between neurological disorders and death by suicide in Denmark","volume":"323","author":"Erlangsen","year":"2020","journal-title":"JAMA."},{"key":"10.1007\/s13311-020-00875-w_bib32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1176\/jnp.6.2.165","article-title":"Parkinson's disease and depression: the relationship to disability and personality","volume":"6","author":"Menza","year":"1994","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences."},{"key":"10.1007\/s13311-020-00875-w_bib33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/archneur.1997.00550170097020","article-title":"Risk factors for depression in Parkinson disease","volume":"54","author":"Tandberg","year":"1997","journal-title":"Archives of Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib34","doi-asserted-by":"crossref","unstructured":"Weintraub D, Caspell-Garcia C, Simuni T, Cho HR, Coffey CS, Aarsland D, et al. Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Ann Clin Transl Neurol. 2020.","DOI":"10.1002\/acn3.51022"},{"key":"10.1007\/s13311-020-00875-w_bib35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/jnnp.49.4.381","article-title":"Depression in Parkinson's disease: a quantitative and qualitative analysis","volume":"49","author":"Gotham","year":"1986","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry."},{"key":"10.1007\/s13311-020-00875-w_bib36","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/mds.23092","article-title":"Depression and subsequent risk of Parkinson's disease in the NIH-AARP Diet and Health Study","volume":"25","author":"Fang","year":"2010","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib37","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2008.152983","article-title":"Use of antidepressants and the risk of Parkinson's disease: a prospective study","volume":"80","author":"Alonso","year":"2009","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry."},{"key":"10.1007\/s13311-020-00875-w_bib38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1474-4422(14)70287-X","article-title":"Prediagnostic presentations of Parkinson's disease in primary care: a case-control study","volume":"14","author":"Schrag","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1007\/s13311-020-00875-w_bib39","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1600-0447.2001.00372.x","article-title":"Increased risk for developing Parkinson's disease for patients with major affective disorder: a register study","volume":"104","author":"Nilsson","year":"2001","journal-title":"Acta Psychiatrica Scandinavica."},{"key":"10.1007\/s13311-020-00875-w_bib40","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1176\/appi.ajp.159.5.746","article-title":"Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease","volume":"159","author":"Mentis","year":"2002","journal-title":"American Journal of Psychiatry."},{"key":"10.1007\/s13311-020-00875-w_bib41","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/mds.21765","article-title":"Morphometric changes of gray matter in Parkinson's disease with depression: a voxel-based morphometry study","volume":"23","author":"Feldmann","year":"2008","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib42","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.neuroimage.2009.04.059","article-title":"Depression in Parkinson's disease: convergence from voxel-based morphometry and functional magnetic resonance imaging in the limbic thalamus","volume":"47","author":"Cardoso","year":"2009","journal-title":"NeuroImage."},{"key":"10.1007\/s13311-020-00875-w_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2009.08.027","article-title":"Transcranial sonography findings related to non-motor features of Parkinson's disease","volume":"289","author":"Walter","year":"2010","journal-title":"Journal of Neurological Science."},{"key":"10.1007\/s13311-020-00875-w_bib44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/bmb\/65.1.193","article-title":"Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment","volume":"65","author":"Mayberg","year":"2003","journal-title":"British Medical Bulletin."},{"key":"10.1007\/s13311-020-00875-w_bib45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1176\/jnp.13.2.222","article-title":"In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease","volume":"13","author":"Murai","year":"2001","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences."},{"key":"10.1007\/s13311-020-00875-w_bib46","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00259-008-0979-7","article-title":"Monoamine transporter availability in Parkinson's disease patients with or without depression","volume":"36","author":"Hesse","year":"2009","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging."},{"key":"10.1007\/s13311-020-00875-w_bib47","unstructured":"Weintraub D, Newberg A, Cary M, Siderowf A, Moberg P, Kleiner-Fisman G, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. Journal of Nuclear Medicine. 2005;46:227-32. PMCID: PMC15695780."},{"key":"10.1007\/s13311-020-00875-w_bib48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00213-010-1867-y","article-title":"Higher dopamine transporter density in Parkinson's disease patients with depression","volume":"211","author":"Felicio","year":"2010","journal-title":"Psychopharmacology."},{"key":"10.1007\/s13311-020-00875-w_bib49","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jns.2017.02.001","article-title":"Association between gene polymorphism and depression in Parkinson's disease: A case-control study","volume":"375","author":"Zheng","year":"2017","journal-title":"Journal of Neurological Science."},{"key":"10.1007\/s13311-020-00875-w_bib50","doi-asserted-by":"crossref","unstructured":"Schrag A, Barone P, Brown R, Leentjens A, McDonald W, Starkstein S, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Movement Disorders. 2007;22:1077-92. PMCID: PMC17394234.","DOI":"10.1002\/mds.21333"},{"key":"10.1007\/s13311-020-00875-w_bib51","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/mds.20723","article-title":"Disease NNWGoDaPs. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS\/NIMH work group","volume":"21","author":"Marsh","year":"2006","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00019442-200203000-00003","article-title":"Provisional diagnostic criteria for depression of Alzheimer disease","volume":"10","author":"Olin","year":"2002","journal-title":"American Journal of Geriatric Psychiatry."},{"issue":"1","key":"10.1007\/s13311-020-00875-w_bib53","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamaneurol.2014.2472","article-title":"Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability","volume":"72","author":"Smith","year":"2015","journal-title":"JAMA Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib54","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1212\/WNL.49.4.1168","article-title":"A survey of antidepressant use in Parkinson's disease","volume":"49","author":"Richard","year":"1997","journal-title":"Neurology."},{"issue":"5","key":"10.1007\/s13311-020-00875-w_bib55","doi-asserted-by":"crossref","first-page":"e0175674","DOI":"10.1371\/journal.pone.0175674","article-title":"Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease","volume":"12","author":"Caspell-Garcia","year":"2017","journal-title":"PLoS One."},{"key":"10.1007\/s13311-020-00875-w_bib56","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-020-00875-w_bib57","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","article-title":"A controlled trial of antidepressants in patients with Parkinson's disease and depression","volume":"72","author":"Menza","year":"2009","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib58","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/mds.21966","article-title":"Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study","volume":"23","author":"Devos","year":"2008","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib59","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e3182516244","article-title":"A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson's disease","volume":"78","author":"Richard","year":"2012","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib60","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.0b013e3181ebdd79","article-title":"Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson's disease","volume":"75","author":"Weintraub","year":"2010","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib61","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Barone","year":"2010","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1007\/s13311-020-00875-w_bib62","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1080\/14656566.2016.1202917","article-title":"Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease","volume":"17","author":"Chung","year":"2016","journal-title":"Expert Opin Pharmacother."},{"issue":"8","key":"10.1007\/s13311-020-00875-w_bib63","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/ene.12724","article-title":"A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients","volume":"22","author":"Barone","year":"2015","journal-title":"Eur J Neurol."},{"key":"10.1007\/s13311-020-00875-w_bib64","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1176\/appi.ajp.2011.10111669","article-title":"Cognitive-behavioral therapy for depression in Parkinson's disease: A randomized, controlled trial","volume":"168","author":"Dobkin","year":"2011","journal-title":"American Journal of Psychiatry."},{"key":"10.1007\/s13311-020-00875-w_bib65","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/0891988708316862","article-title":"How depressed Parkinson's disease patients view the etiology and treatment of depression","volume":"21","author":"Oehlberg","year":"2008","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"issue":"7","key":"10.1007\/s13311-020-00875-w_bib66","doi-asserted-by":"crossref","first-page":"e0181515","DOI":"10.1371\/journal.pone.0181515","article-title":"Effectiveness of physical activity on patients with depression and Parkinson's disease: A systematic review","volume":"12","author":"Wu","year":"2017","journal-title":"PLoS One."},{"issue":"4","key":"10.1007\/s13311-020-00875-w_bib67","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.mehy.2009.06.053","article-title":"ECT for Parkinson's disease","volume":"73","author":"Popeo","year":"2009","journal-title":"Med Hypotheses."},{"issue":"9","key":"10.1007\/s13311-020-00875-w_bib68","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/jnnp-2013-306090","article-title":"Which target is best for patients with Parkinson's disease? A meta-analysis of pallidal and subthalamic stimulation","volume":"85","author":"Sako","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"6","key":"10.1007\/s13311-020-00875-w_bib69","doi-asserted-by":"crossref","first-page":"e0156721","DOI":"10.1371\/journal.pone.0156721","article-title":"Cognitive and psychiatric effects of STN versus GPi deep brain stimulation in Parkinson's disease: a meta-analysis of randomized controlled trials","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One."},{"key":"10.1007\/s13311-020-00875-w_bib70","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2008.929","article-title":"Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized clinical trial","volume":"301","author":"Weaver","year":"2009","journal-title":"JAMA."},{"issue":"1","key":"10.1007\/s13311-020-00875-w_bib71","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1212\/WNL.0000000000007665","article-title":"Suicide and suicide attempts after subthalamic nucleus stimulation in Parkinson disease","volume":"93","author":"Giannini","year":"2019","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib72","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1093\/brain\/awn214","article-title":"A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease","volume":"131","author":"Voon","year":"2008","journal-title":"Brain."},{"key":"10.1007\/s13311-020-00875-w_bib73","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/jnnp-2012-304396","article-title":"Suicide ideation and behaviors after STN and GPi DBS surgery for Parkinson's disease: results from a randomized, controlled trial","volume":"84","author":"Weintraub","year":"2013","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry."},{"key":"10.1007\/s13311-020-00875-w_bib74","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/jnp.8.4.383","article-title":"Anxiety and Parkinson's disease","volume":"8","author":"Richard","year":"1996","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences."},{"key":"10.1007\/s13311-020-00875-w_bib75","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/mds.22221","article-title":"Frequency of social phobia and psychometric properties of the Liebowitz social anxiety scale in Parkinson's disease","volume":"23","author":"Kummer","year":"2008","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib76","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/mds.22611","article-title":"Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease","volume":"24","author":"Pontone","year":"2009","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib77","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/mds.22833","article-title":"Anxiety disorders in Parkinson's disease: prevalence and risk factors","volume":"25","author":"Dissanayaka","year":"2010","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib78","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0006-3223(93)90237-8","article-title":"Parkinson's disease and anxiety: comorbidity with depression","volume":"34","author":"Menza","year":"1993","journal-title":"Biological Psychiatry."},{"key":"10.1007\/s13311-020-00875-w_bib79","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/mds.870120607","article-title":"Symptoms and duration of the prodromal phase in Parkinson's disease","volume":"12","author":"Gonera","year":"1997","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib80","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/1531-8257(200007)15:4<669::AID-MDS1011>3.0.CO;2-5","article-title":"Anxiety disorders and depressive disorders preceding Parkinson's Disease: a case-control study","volume":"15","author":"Shiba","year":"2000","journal-title":"Movement Disorders."},{"issue":"8","key":"10.1007\/s13311-020-00875-w_bib81","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/mds.25919","article-title":"The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale","volume":"29","author":"Leentjens","year":"2014","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-020-00875-w_bib82","doi-asserted-by":"crossref","unstructured":"Reynolds GO, Saint-Hilaire M, Thomas CA, Barlow DH, Cronin-Golomb A. Cognitive-behavioral therapy for anxiety in Parkinson's disease. Behav Modif. 2019:145445519838828.","DOI":"10.1177\/0145445519838828"},{"issue":"2","key":"10.1007\/s13311-020-00875-w_bib83","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3233\/JPD-2012-12080","article-title":"Cognitive behavioral therapy for depression and anxiety in Parkinson's disease: a clinical review","volume":"2","author":"Armento","year":"2012","journal-title":"J Parkinsons Dis."},{"key":"10.1007\/s13311-020-00875-w_bib84","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/01.wnl.0000191325.31068.c4","article-title":"Hallucinations in Parkinson disease in the prelevodopa era","volume":"66","author":"F\u00e9nelon","year":"2006","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mds.26432","article-title":"Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase","volume":"31","author":"Pagonabarraga","year":"2016","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib86","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1212\/WNL.55.2.281","article-title":"Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis","volume":"55","author":"Arnulf","year":"2000","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib87","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneurol.2010.166","article-title":"A 12-year population-based study of psychosis in Parkinson disease","volume":"67","author":"Forsaa","year":"2010","journal-title":"Archives of Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib88","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.parkreldis.2007.05.009","article-title":"A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia","volume":"14","author":"McKinlay","year":"2008","journal-title":"Parkinsonism and Related Disorders."},{"issue":"3","key":"10.1007\/s13311-020-00875-w_bib89","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3233\/JPD-150597","article-title":"Impact of neuropsychiatric symptoms on the quality of life of subjects with Parkinson's disease","volume":"5","author":"Alvarado-Bolanos","year":"2015","journal-title":"J Parkinsons Dis."},{"issue":"4","key":"10.1007\/s13311-020-00875-w_bib90","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1155\/2013\/645429","article-title":"Parkinson disease psychosis: Update","volume":"27","author":"Friedman","year":"2013","journal-title":"Behav Neurol."},{"key":"10.1007\/s13311-020-00875-w_bib91","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/WNL.0b013e3181f61311","article-title":"What predicts mortality in Parkinson disease? A prospective population-based long-term study","volume":"75","author":"Forsaa","year":"2010","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib92","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1532-5415.2000.tb06891.x","article-title":"al e. Predictors of nursing home placement in Parkinson's Disease: a population-based, prospective study","volume":"48","author":"Aarsland","year":"2000","journal-title":"Journal of the American Geriatrics Society."},{"key":"10.1007\/s13311-020-00875-w_bib93","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","article-title":"Risk factors for nursing home placement in advanced Parkinson's disease","volume":"43","author":"Goetz","year":"1993","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib94","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1212\/01.WNL.0000068010.82167.CF","article-title":"Longitudinal outcome of Parkinson's disease patients with psychosis","volume":"60","author":"Factor","year":"2003","journal-title":"Neurology."},{"issue":"5","key":"10.1007\/s13311-020-00875-w_bib95","first-page":"257","article-title":"Factors associated with the quality of life of subjects with Parkinson's disease and burden on their caregivers","volume":"30","author":"Rodriguez-Violante","year":"2015","journal-title":"Neurologia."},{"key":"10.1007\/s13311-020-00875-w_bib96","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.parkreldis.2005.06.011","article-title":"Caregiver-burden in Parkinson's disease is closely associated with psychiatric symptoms, falls, and disability","volume":"12","author":"Schrag","year":"2006","journal-title":"Parkinsonism and Related Disorders."},{"issue":"11","key":"10.1007\/s13311-020-00875-w_bib97","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00702-009-0302-1","article-title":"Admission of Parkinsonian patients to a neurological ward in a community hospital","volume":"116","author":"Klein","year":"2009","journal-title":"J Neural Transm (Vienna)."},{"issue":"2","key":"10.1007\/s13311-020-00875-w_bib98","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/mds.23449","article-title":"Clinical problems in the hospitalized Parkinson's disease patient: systematic review","volume":"26","author":"Gerlach","year":"2011","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-020-00875-w_bib99","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/mds.22839","article-title":"The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria","volume":"25","author":"Fenelon","year":"2010","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib100","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/09540260020002541","article-title":"Psychosis in Parkinson's disease: \u2018between a rock and a hard place\u2018","volume":"12","author":"Henderson","year":"2000","journal-title":"International Review of Psychiatry."},{"key":"10.1007\/s13311-020-00875-w_bib101","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/1099-1166(200102)16:2<184::AID-GPS304>3.0.CO;2-K","article-title":"Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease","volume":"16","author":"Aarsland","year":"2001","journal-title":"International Journal of Geriatric Psychiatry."},{"key":"10.1007\/s13311-020-00875-w_bib102","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/mds.20582","article-title":"Relationship between hallucinatons, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease","volume":"20","author":"Pacchetti","year":"2005","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib103","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archneur.1996.00550120077019","article-title":"Visual hallucinations associated with Parkinson disease","volume":"53","author":"Sanchez-Ramos","year":"1996","journal-title":"Archives of Neurology."},{"issue":"2","key":"10.1007\/s13311-020-00875-w_bib104","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1212\/WNL.50.2.515","article-title":"Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations","volume":"50","author":"Goetz","year":"1998","journal-title":"Neurology."},{"issue":"Suppl 3","key":"10.1007\/s13311-020-00875-w_bib105","first-page":"S10","article-title":"Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment","volume":"52","author":"Wolters","year":"1999","journal-title":"Neurology."},{"issue":"Suppl 3","key":"10.1007\/s13311-020-00875-w_bib106","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/PL00007822","article-title":"Intrinsic and extrinsic psychosis in Parkinson's disease","volume":"248","author":"Wolters","year":"2001","journal-title":"Journal of Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib107","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1093\/brain\/awp166","article-title":"Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease","volume":"132","author":"Manganelli","year":"2009","journal-title":"Brain."},{"issue":"10","key":"10.1007\/s13311-020-00875-w_bib108","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/mds.23083","article-title":"Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations","volume":"25","author":"Huot","year":"2010","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-020-00875-w_bib109","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archneurol.2010.35","article-title":"Serotonin 2A receptors and visual hallucinations in Parkinson disease","volume":"67","author":"Ballanger","year":"2010","journal-title":"Archives of Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/mds.22919","article-title":"Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies","volume":"25","author":"Kurita","year":"2010","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib111","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/mds.22258","article-title":"Brain response to complex visual stimuli in Parkinson's patients with hallucinations: a functional magnetic resonance imaging study","volume":"23","author":"Ramirez-Ruiz","year":"2008","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib112","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/archneur.64.7.984","article-title":"Metabolic alterations in patients with Parkinson disease and visual hallucinations","volume":"64","author":"Boecker","year":"2007","journal-title":"Archives of Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib113","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/mds.22873","article-title":"Frontal and associative visual areas related to visual hallucinations in dementia with Lewy bodies and Parkinson's disease with dementia","volume":"25","author":"Sanchez-Castaneda","year":"2010","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib114","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/jnnp.2009.179655","article-title":"Differential progression of brain atrophy in Parkinson's disease with and without visual hallucinations","volume":"81","author":"Ibarretxe-Bilbao","year":"2010","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry."},{"key":"10.1007\/s13311-020-00875-w_bib115","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/brain\/awt360","article-title":"deToledo-Morrell L, et al. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations","volume":"137","author":"Goldman","year":"2014","journal-title":"Brain."},{"key":"10.1007\/s13311-020-00875-w_bib116","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1001\/archneur.61.8.1280","article-title":"Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system","volume":"61","author":"Goldman","year":"2004","journal-title":"Archives of Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib117","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jns.2016.03.005","article-title":"Genetic substrates of psychosis in patients with Parkinson's disease: A critical review","volume":"364","author":"Lenka","year":"2016","journal-title":"J Neurol Sci."},{"key":"10.1007\/s13311-020-00875-w_bib118","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/mds.21875","article-title":"Scales to assess psychosis in Parkinson's disease: critique and recommendations","volume":"23","author":"Fernandez","year":"2008","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib119","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet."},{"issue":"3","key":"10.1007\/s13311-020-00875-w_bib120","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.parkreldis.2012.10.022","article-title":"Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis","volume":"19","author":"Voss","year":"2013","journal-title":"Parkinsonism Relat Disord."},{"key":"10.1007\/s13311-020-00875-w_bib121","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1136\/jnnp.2008.153163","article-title":"Impact of standard of care for psychosis in Parkinson disease","volume":"79","author":"Thomsen","year":"2008","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry."},{"issue":"Supplement 4","key":"10.1007\/s13311-020-00875-w_bib122","first-page":"S1","article-title":"The scientific and clinical basis of the treatment of Parkinson disease (2009)","volume":"72","author":"Olanow","year":"2009","journal-title":"Neurology"},{"issue":"6","key":"10.1007\/s13311-020-00875-w_bib123","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9","article-title":"Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial","volume":"15","author":"Mohr","year":"2000","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-020-00875-w_bib124","doi-asserted-by":"crossref","unstructured":"Nichols MJ, Hartlein JM, Eicken MG, Racette BA, Black KJ. A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease. F1000Res. 2013;2:150.","DOI":"10.12688\/f1000research.2-150.v1"},{"key":"10.1007\/s13311-020-00875-w_bib125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00002826-200401000-00003","article-title":"Aripiprazole for drug-induced psyhcosis in Parkinson's disease: preliminary experience","volume":"27","author":"Fernandez","year":"2004","journal-title":"Clinical Neuropharmacology."},{"issue":"5","key":"10.1007\/s13311-020-00875-w_bib126","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamaneurol.2016.0031","article-title":"Association of antipsychotic use with mortality risk in patients with Parkinson disease","volume":"73","author":"Weintraub","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1007\/s13311-020-00875-w_bib127","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jagp.2017.01.076","article-title":"Antipsychotic use and physical morbidity in Parkinson disease","volume":"25","author":"Weintraub","year":"2017","journal-title":"Am J Geriatr Psychiatry."},{"key":"10.1007\/s13311-020-00875-w_bib128","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","article-title":"Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease","volume":"20","author":"Ondo","year":"2005","journal-title":"Movement Disorders"},{"key":"10.1007\/s13311-020-00875-w_bib129","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.21116","article-title":"Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration","volume":"22","author":"Rabey","year":"2007","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib130","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/NDT.S5335","article-title":"A randomized controlled trial of quetiapine for psychosis in Parkinson's disease","volume":"5","author":"Shotbolt","year":"2009","journal-title":"Neuropsychiatric Disease and Treatment."},{"key":"10.1007\/s13311-020-00875-w_bib131","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease","volume":"340","author":"Group TPS","year":"1999","journal-title":"New England Journal of Medicine."},{"key":"10.1007\/s13311-020-00875-w_bib132","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","article-title":"Clozapine in drug-induced psychosis in Parkinson's disease","volume":"353","author":"Group TFCPS","year":"1999","journal-title":"The Lancet."},{"key":"10.1007\/s13311-020-00875-w_bib133","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up","volume":"75","author":"Pollak","year":"2004","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1007\/s13311-020-00875-w_bib134","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archneurol.2011.139","article-title":"Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis","volume":"68","author":"Weintraub","year":"2011","journal-title":"Archives of Neurology."},{"issue":"3","key":"10.1007\/s13311-020-00875-w_bib135","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","article-title":"Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study","volume":"17","author":"Ballard","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1007\/s13311-020-00875-w_bib136","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jagp.2018.06.001","article-title":"Perspective on pimavanserin and the SAPS-PD: novel scale development as a means to FDA approval","volume":"26","author":"Schubmehl","year":"2018","journal-title":"American Journal of Geriatric Psychiatry."},{"issue":"7","key":"10.1007\/s13311-020-00875-w_bib137","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1474-4422(18)30209-6","article-title":"Difficult choices in treating Parkinson's disease psychosis","volume":"17","author":"The_Lancet_Neurology","year":"2018","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1007\/s13311-020-00875-w_bib138","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/mds.27488","article-title":"Pimavanserin for Parkinson's disease psychosis: effects stratified by baseline cognition and use of cognitive-enhancing medications","volume":"33","author":"Espay","year":"2018","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-020-00875-w_bib139","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1212\/01.WNL.0000076478.45005.EC","article-title":"Pathological gambling associated with dopamine agonist therapy in Parkinson's disease","volume":"61","author":"Driver-Dunckley","year":"2003","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib140","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/archneur.64.8.1089","article-title":"Medication-related impulse control and repetitive behaviors in Parkinson disease","volume":"64","author":"Voon","year":"2007","journal-title":"Archives of Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib141","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archneur.63.7.969","article-title":"Association of dopamine agonist use with impulse control disorders in Parkinson disease","volume":"63","author":"Weintraub","year":"2006","journal-title":"Archives of Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib142","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1212\/WNL.0b013e31827b915c","article-title":"Parkinson's Progression Markers Initiative. Screening for impulse control disorder symptoms in patients with de novo Parkinson disease: a case-control study","volume":"80","author":"Weintraub","year":"2013","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib143","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.parkreldis.2010.11.015","article-title":"Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: Validity and variability","volume":"17","author":"Papay","year":"2011","journal-title":"Parkinsonism and Related Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib144","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: A cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Archives of Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib145","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1212\/WNL.0000000000005816","article-title":"Longitudinal analysis of impulse control disorders in Parkinson disease","volume":"91","author":"Corvol","year":"2018","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib146","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/mds.27181","article-title":"Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study","volume":"32","author":"Biundo","year":"2017","journal-title":"Mov Disord."},{"issue":"10","key":"10.1007\/s13311-020-00875-w_bib147","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/ene.13078","article-title":"Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis","volume":"23","author":"Antonini","year":"2016","journal-title":"Eur J Neurol."},{"key":"10.1007\/s13311-020-00875-w_bib148","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ana.22164","article-title":"Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study","volume":"68","author":"Weintraub","year":"2010","journal-title":"Annals of Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib149","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/jnnp-2013-306787","article-title":"Impulse control disorders in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study","volume":"85","author":"Garcia-Ruiz","year":"2014","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry."},{"key":"10.1007\/s13311-020-00875-w_bib150","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.parkreldis.2007.05.006","article-title":"Predictors of impulsivity and reward seeking behavior with dopamine agonists","volume":"14","author":"Ondo","year":"2008","journal-title":"Parkinsonism and Related Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib151","first-page":"81","article-title":"Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study","volume":"33","author":"Cornelius","year":"2010","journal-title":"Sleep."},{"key":"10.1007\/s13311-020-00875-w_bib152","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10899-009-9123-2","article-title":"Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia","volume":"25","author":"Holman","year":"2009","journal-title":"Journal of Gambling Studies."},{"issue":"6","key":"10.1007\/s13311-020-00875-w_bib153","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study","volume":"80","author":"Bancos","year":"2014","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.1007\/s13311-020-00875-w_bib154","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/ana.22356","article-title":"Impulse control disorders in Parkinson disease: a multicenter case-control study","volume":"69","author":"Voon","year":"2011","journal-title":"Annals of Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib155","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","article-title":"Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies","volume":"68","author":"Giovannoni","year":"2000","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry."},{"key":"10.1007\/s13311-020-00875-w_bib156","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.20045","article-title":"Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome","volume":"19","author":"Evans","year":"2004","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib157","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/mds.21296","article-title":"Punding prevalence in Parkinson's disease","volume":"22","author":"Miyasaki","year":"2007","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib158","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00213-009-1697-y","article-title":"Impulsive choice and response in dopamine agonist-related impulse control behaviors","volume":"207","author":"Voon","year":"2010","journal-title":"Psychopharmacology."},{"key":"10.1007\/s13311-020-00875-w_bib159","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/npp.2010.84","article-title":"Intact reward learning but elevated delay discounting in Parkinson's disease patients with impulsive-compulsive spectrum behaviors","volume":"35","author":"Housden","year":"2010","journal-title":"Neuropsychopharmacology."},{"key":"10.1007\/s13311-020-00875-w_bib160","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/mds.22472","article-title":"Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease","volume":"24","author":"Santangelo","year":"2009","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib161","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3389\/fneur.2018.00654","article-title":"Impulse control disorder in Parkinson's disease: a eta-analysis of cognitive, affective, and motivational correlates","volume":"9","author":"Martini","year":"2018","journal-title":"Front Neurol."},{"key":"10.1007\/s13311-020-00875-w_bib162","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/ana.20822","article-title":"Compulsive drug use linked to sensitized ventral striatal dopamine transmission","volume":"59","author":"Evans","year":"2006","journal-title":"Annals of Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib163","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/brain\/awp054","article-title":"Increased striatal dopamine release in parkinsonian patients with pathological gambling: a 11C raclopride PET study","volume":"132","author":"Steeves","year":"2009","journal-title":"Brain."},{"key":"10.1007\/s13311-020-00875-w_bib164","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.nbd.2012.06.021","article-title":"Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: A [11C] FLB-457 and PET study","volume":"48","author":"Ray","year":"2012","journal-title":"Neurobiology of Disease."},{"key":"10.1007\/s13311-020-00875-w_bib165","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.nbd.2010.03.013","article-title":"Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling","volume":"39","author":"Cilia","year":"2010","journal-title":"Neurobiology of Disease."},{"key":"10.1007\/s13311-020-00875-w_bib166","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuron.2009.12.027","article-title":"Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors","volume":"65","author":"Voon","year":"2010","journal-title":"Neuron."},{"key":"10.1007\/s13311-020-00875-w_bib167","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/mds.23147","article-title":"Decreased ventral striatal activity with impulse control disorders in Parkinson's disease","volume":"25","author":"Rao","year":"2010","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib168","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/mds.27047","article-title":"Mesocorticolimbic hemodynamic response in Parkinson's disease patients with compulsive behaviors","volume":"32","author":"Claassen","year":"2017","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-020-00875-w_bib169","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/brain\/aws326","article-title":"Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease","volume":"136","author":"Politis","year":"2013","journal-title":"Brain."},{"issue":"8","key":"10.1007\/s13311-020-00875-w_bib170","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/jnnp-2015-311827","article-title":"Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease","volume":"87","author":"Smith","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"10","key":"10.1007\/s13311-020-00875-w_bib171","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/jnnp-2015-312848","article-title":"Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease","volume":"87","author":"Kraemmer","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"12","key":"10.1007\/s13311-020-00875-w_bib172","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/mds.27519","article-title":"Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease","volume":"33","author":"Cormier-Dequaire","year":"2018","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-020-00875-w_bib173","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/mds.22571","article-title":"Validation of the Questionnaire for Impulsive-Compulsive Behaviors in Parkinson's Disease (QUIP)","volume":"24","author":"Weintraub","year":"2009","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib174","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/mds.24023","article-title":"Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale","volume":"27","author":"Weintraub","year":"2012","journal-title":"Movement Disorders."},{"issue":"5","key":"10.1007\/s13311-020-00875-w_bib175","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/mds.26223","article-title":"International validation of a behavioral scale in Parkinson's disease without dementia","volume":"30","author":"Rieu","year":"2015","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-020-00875-w_bib176","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/mdc3.12316","article-title":"Parkinson's Impulse Control Scale (PICS) for the rating of severity of impulsive compulsive behaviors in Parkinson's disease","volume":"3","author":"Okai","year":"2016","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib177","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/mds.25291","article-title":"Prospective cohort study of impulse control disorders in Parkinson's disease","volume":"28","author":"Bastiaens","year":"2013","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib178","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mds.21770","article-title":"Long-term follow-up of impulse control disorders in Parkinson's disease","volume":"23","author":"Mamikonyan","year":"2008","journal-title":"Movement Disorders"},{"key":"10.1007\/s13311-020-00875-w_bib179","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/archneurol.2009.294","article-title":"Dopamine agonist withdrawal syndrome in Parkinson disease","volume":"67","author":"Rabinak","year":"2010","journal-title":"Archives of Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib180","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/mds.21098","article-title":"Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation","volume":"21","author":"Ardouin","year":"2006","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib181","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/jnnp-2017-316373","article-title":"Subthalamic stimulation and neuropsychiatric symptoms in Parkinson's disease: results from a long-term follow-up cohort study","volume":"89","author":"Abbes","year":"2018","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry."},{"issue":"3","key":"10.1007\/s13311-020-00875-w_bib182","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1474-4422(18)30035-8","article-title":"Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial","volume":"17","author":"Lhommee","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1007\/s13311-020-00875-w_bib183","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/brain\/aws078","article-title":"Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviors","volume":"135","author":"Lhomm\u00e9e","year":"2012","journal-title":"Brain."},{"key":"10.1007\/s13311-020-00875-w_bib184","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/jnnp.2006.102061","article-title":"Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease","volume":"78","author":"Smeding","year":"2007","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry."},{"key":"10.1007\/s13311-020-00875-w_bib185","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1002\/mds.25735","article-title":"Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?","volume":"28","author":"Okun","year":"2013","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib186","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ana.22029","article-title":"Pathological gambling in Parkinson disease is reduced by amantadine","volume":"68","author":"Thomas","year":"2010","journal-title":"Annals of Neurology."},{"issue":"9","key":"10.1007\/s13311-020-00875-w_bib187","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/WNL.0000000000000729","article-title":"Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study","volume":"83","author":"Papay","year":"2014","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib188","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1212\/WNL.0b013e3182840678","article-title":"Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers","volume":"80","author":"Okai","year":"2013","journal-title":"Neurology."},{"issue":"Suppl. 14","key":"10.1007\/s13311-020-00875-w_bib189","doi-asserted-by":"crossref","first-page":"S305","DOI":"10.1002\/mds.20963","article-title":"Deep brain stimulation: neuropsychological and neuropsychiatric issues","volume":"21","author":"Voon","year":"2006","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib190","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/mds.21551","article-title":"Psychiatric and neuropsychiatric adverse events associated with deep brain stimluation: a meta-analysis of ten years' experience","volume":"22","author":"Appleby","year":"2007","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib191","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa060281","article-title":"A randomized trial of deep-brain stimulation for Parkinson's disease","volume":"355","author":"Deuschl","year":"2006","journal-title":"New England Journal of Medicine."},{"key":"10.1007\/s13311-020-00875-w_bib192","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(08)70114-5","article-title":"Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study","volume":"7","author":"Witt","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1007\/s13311-020-00875-w_bib193","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1056\/NEJMoa0907083","article-title":"Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease","volume":"362","author":"Follett","year":"2010","journal-title":"New England Journal of Medicine."},{"key":"10.1007\/s13311-020-00875-w_bib194","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1212\/WNL.59.3.408","article-title":"Nonmotor fluctuations in Parkinson's disease: frequent and disabling","volume":"59","author":"Witjas","year":"2002","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib195","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1176\/jnp.14.4.438","article-title":"Clinical features and comorbidity of mood fluctuations in Parkinson's disease","volume":"14","author":"Racette","year":"2002","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences."},{"key":"10.1007\/s13311-020-00875-w_bib196","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1176\/jnp.13.1.35","article-title":"Relationship between mood and motor fluctuations in Parkinson's disease","volume":"13","author":"Richard","year":"2001","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences."},{"key":"10.1007\/s13311-020-00875-w_bib197","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/mds.21205","article-title":"Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: a double-blind study","volume":"22","author":"Kulisevsky","year":"2007","journal-title":"Movement Disorders"},{"key":"10.1007\/s13311-020-00875-w_bib198","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mds.870100316","article-title":"Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings","volume":"10","author":"Maricle","year":"1995","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib199","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1176\/jnp.4.2.134","article-title":"Reliability, validity, and clinical correlates of apathy in Parkinson's disease","volume":"4","author":"Starkstein","year":"1992","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences."},{"key":"10.1007\/s13311-020-00875-w_bib200","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/mds.22577","article-title":"The syndromic validity and nosological position of apathy in Parkinson's disease","volume":"24","author":"Starkstein","year":"2009","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib201","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1212\/01.wnl.0000230572.07791.22","article-title":"Dissociating apathy and depression in Parkinson disease","volume":"67","author":"Kirsch-Darrow","year":"2006","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib202","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/mds.10041","article-title":"Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease","volume":"17","author":"Isella","year":"2002","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib203","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/mds.23268","article-title":"Neuroanatomical correlates of apathy in Parkinson's disease: a magnetic resonance imaging study using voxel-based morphometry","volume":"25","author":"Reijnders","year":"2010","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib204","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/brain\/awt067","article-title":"Parkinsonian apathy responds to dopaminergic stimulation of D2\/D3 receptors with piribedil","volume":"136","author":"Thobois","year":"2013","journal-title":"Brain."},{"key":"10.1007\/s13311-020-00875-w_bib205","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12883-016-0610-7","article-title":"Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease","volume":"16","author":"Hauser","year":"2016","journal-title":"BMC Neurol."},{"issue":"6","key":"10.1007\/s13311-020-00875-w_bib206","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/jnnp-2013-306439","article-title":"Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial","volume":"85","author":"Devos","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1007\/s13311-020-00875-w_bib207","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.parkreldis.2009.01.001","article-title":"Involuntary emotional disorder in Parkinson's disease","volume":"15","author":"Phuong","year":"2009","journal-title":"Parkinsonism and Related Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib208","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40734-015-0023-6","article-title":"Pseudobulbar laughter as a levodopa off phenomenon exacerbated by subthalamic deep brain stimulation","volume":"2","author":"Chattha","year":"2015","journal-title":"J Clin Mov Disord."},{"key":"10.1007\/s13311-020-00875-w_bib209","first-page":"195","article-title":"Regulation of affect","volume":"3","author":"Green","year":"1998","journal-title":"Seminars in Clinical Neuropsychiatry."},{"key":"10.1007\/s13311-020-00875-w_bib210","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1053\/scnp.2000.9554","article-title":"The neuropsychiatry of pathologic affect: an approach to evaluation and treatment","volume":"5","author":"Arciniegas","year":"2000","journal-title":"Seminars in Clinical Neuropsychiatry."},{"key":"10.1007\/s13311-020-00875-w_bib211","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.20828","article-title":"Randomized, controlled trial of dextromethorphan\/quinidine for pseudobulbar affect in multiple sclerosis","volume":"59","author":"Panitch","year":"2006","journal-title":"Annals of Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib212","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1212\/01.WNL.0000142042.50528.2F","article-title":"Treatment of pseudobulbar affect in ALS with dextromethorphan\/quinidine: a randomized trial","volume":"63","author":"Brooks","year":"2004","journal-title":"Neurology."},{"issue":"Suppl 1","key":"10.1007\/s13311-020-00875-w_bib213","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.parkreldis.2015.09.027","article-title":"Non motor subtypes and Parkinson's disease","volume":"22","author":"Sauerbier","year":"2016","journal-title":"Parkinsonism Relat Disord."},{"key":"10.1007\/s13311-020-00875-w_bib214","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1097\/JGP.0b013e3181b215ec","article-title":"Use of latent variable modeling to delineate psychiatric and cognitive profiles in Parkinson's disease","volume":"17","author":"Mavandadi","year":"2009","journal-title":"American Journal of Geriatric Psychiatry."},{"key":"10.1007\/s13311-020-00875-w_bib215","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1136\/jnnp.2008.166629","article-title":"Patterns of motor and non-motor features in Parkinson's disease","volume":"80","author":"van Rooden","year":"2009","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry."},{"key":"10.1007\/s13311-020-00875-w_bib216","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fnagi.2017.00301","article-title":"Parkinson's disease subtypes identified from cluster analysis of motor and non-motor symptoms","volume":"9","author":"Mu","year":"2017","journal-title":"Front Aging Neurosci."},{"issue":"2","key":"10.1007\/s13311-020-00875-w_bib217","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mds.25799","article-title":"Nonmotor symptoms and health-related quality of life in early Parkinson's disease","volume":"29","author":"Martinez-Martin","year":"2014","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-020-00875-w_bib218","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/mds.21596","article-title":"The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study","volume":"22","author":"Chaudhuri","year":"2007","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib219","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1002\/mds.21696","article-title":"Assessment of psychiatric complications in Parkinson's disease: The SCOPA-PC","volume":"22","author":"Visser","year":"2007","journal-title":"Movement Disorders."},{"key":"10.1007\/s13311-020-00875-w_bib220","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology."},{"key":"10.1007\/s13311-020-00875-w_bib221","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and climimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Movement Disorders."},{"issue":"1","key":"10.1007\/s13311-020-00875-w_bib222","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/mds.27862","article-title":"The Movement Disorder Society Nonmotor Rating Scale: Initial validation study","volume":"35","author":"Chaudhuri","year":"2020","journal-title":"Mov Disord."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00875-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-020-00875-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923012564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923012564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00875-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:03:14Z","timestamp":1761807794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923012564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":222,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1878747923012564"],"URL":"https:\/\/doi.org\/10.1007\/s13311-020-00875-w","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of psychiatric disorders in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-020-00875-w","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}